Agilent Technologies, Inc. Q3 2026 Earnings Recap

Shares rose modestly by 1.9% following Agilent’s Q3 report, reflecting a solid quarter marked by above-guidance revenue growth and margin expansion, though the market remained cautious given the tempered strength in diagnostics and clinical segments.

Key Takeaways

• Reported revenue of $1.88 billion grew 7.3% on a core basis, beating the high end of guidance by 140 basis points.
• Operating margin was 27.2% ex-tariff refunds, 80 basis points above implied guidance; total margin including $20 million tariff refunds reached 28.3%.
• Earnings per share of $1.56 (ex-refund) exceeded the high end of guidance by $0.06, representing 14% year-over-year growth.
• Pharma segment grew 12%, outperforming expectations and peers, driven by strong demand in large and smaller biotech customers.
• Diagnostics and clinical revenue was slightly below high single-digit guidance, though underlying orders grew robustly, leaving some uncertainty around near-term segment momentum.